Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Other Accumulated Expenses (2021 - 2026)

Atara Biotherapeutics filings provide 6 years of Other Accumulated Expenses readings, the most recent being $41000.0 for Q1 2026.

  • On a quarterly basis, Other Accumulated Expenses fell 97.7% to $41000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $41000.0, a 97.7% decrease, with the full-year FY2025 number at $3.0 million, up 1277.78% from a year prior.
  • Other Accumulated Expenses hit $41000.0 in Q1 2026 for Atara Biotherapeutics, down from $3.0 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $26.1 million in Q2 2024 to a low of $41000.0 in Q1 2026.
  • Median Other Accumulated Expenses over the past 5 years was $7.7 million (2025), compared with a mean of $11.0 million.
  • Biggest five-year swings in Other Accumulated Expenses: soared 5343.26% in 2023 and later tumbled 98.76% in 2024.
  • Atara Biotherapeutics' Other Accumulated Expenses stood at $319000.0 in 2022, then soared by 5343.26% to $17.4 million in 2023, then tumbled by 98.76% to $216000.0 in 2024, then soared by 1277.78% to $3.0 million in 2025, then tumbled by 98.62% to $41000.0 in 2026.
  • The last three reported values for Other Accumulated Expenses were $41000.0 (Q1 2026), $3.0 million (Q4 2025), and $4.6 million (Q3 2025) per Business Quant data.